Does Glofitamab, when used in combination with the “Pola-R-CHP” treatment regimen, provide additional benefit compared to “Pola-R-CHP” alone in patients with untreated large B-cell lymphoma?

Large B-cell lymphomas (LBCL) are a subgroup of non-Hodgkin lymphomas and affect B lymphocytes, a type of white blood cell that is part of the immune system. There are several subtypes of LBCL. These conditions can cause, among other things, rapid enlargement of the lymph nodes and spread to other organs. Other symptoms include fever, night sweats, and weight loss. The exact cause of LBCL is unknown, but genetic mutations and infections such as the Epstein-Barr virus (EBV) may play a role. Patients with newly diagnosed LBCL are typically treated with a combination of chemotherapy and immunotherapy. In recent years, a new treatment regimen has become established alongside the classic R-CHOP regimen: Pola-R-CHP. Pola-R-CHP consists of polatuzumab vedotin, rituximab, cyclophosphamide, doxorubicin, and prednisone. Treatment depends, among other factors, on the patient’s overall health, the subtype, and the progression of the disease. Glofitamab is a special bispecific antibody that can bind simultaneously to cancer cells (CD20) and to the body’s own healthy immune cells (T cells, via CD3). In this way, the drug helps the immune system recognize and destroy the cancer cells. The drug is already approved for the treatment of subtypes of relapsed/refractory LBCL.

This Phase 3 study is investigating the efficacy and safety of the combination therapy of glofitamab and Pola-R-CHP compared to Pola-R-CHP therapy alone in a larger number of patients. As part of the study, patients will be randomly assigned to two groups. Group 1 will receive the combination therapy of glofitamab and Pola-R-CHP, and Group 2 will receive treatment with Pola-R-CHP. A total of 8 cycles will be administered over a period of approximately 6 months. The study is open-label, meaning that both medical staff and patients know which medications are being administered. Treatments and follow-up examinations as part of the study will continue for up to 5.5 years, during which the effectiveness of the therapy and the occurrence of side effects from the various medications will be evaluated. The key factor is whether or when the disease progresses again during treatment. The primary endpoint of the study is progression-free survival.

Patients between the ages of 18 and 80 with untreated LBCL are eligible to participate in the study. This includes patients with diffuse large B-cell lymphoma (DLBCL) without a specific subtype, DLBCL with MYC, BCL2, and/or BCL6 gene alterations, high-grade B-cell lymphoma, transformed lymphoma arising from a previous low-grade lymphoma, and DLBCL with transitional patterns to other aggressive forms of lymphoma. The cancer cells must express the surface protein CD20 (CD20-positive). The study excludes certain subtypes, including grade 3B follicular lymphoma, transformed indolent B-cell lymphomas, primary mediastinal (thymic) large B-cell lymphomas, Burkitt lymphomas, primary large B-cell lymphomas of so-called immunoprivileged sites (such as the brain, eye, or testicles), and lymphomas of the central nervous system.